SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-016635
Filing Date
2022-08-11
Accepted
2022-08-11 07:07:24
Documents
13
Period of Report
2022-08-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fnch-20220811.htm   iXBRL 8-K 57628
2 EX-99.1 fnch-ex99_1.htm EX-99.1 173161
  Complete submission text file 0000950170-22-016635.txt   360542

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fnch-20220811_pre.xml EX-101.PRE 9850
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fnch-20220811_lab.xml EX-101.LAB 13342
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fnch-20220811.xsd EX-101.SCH 2484
7 EXTRACTED XBRL INSTANCE DOCUMENT fnch-20220811_htm.xml XML 4711
Mailing Address 200 INNER BELT ROAD SOMERVILLE MA 02143
Business Address 200 INNER BELT ROAD SOMERVILLE MA 02143 617-229-6499
Finch Therapeutics Group, Inc. (Filer) CIK: 0001733257 (see all company filings)

IRS No.: 823433558 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40227 | Film No.: 221153643
SIC: 2836 Biological Products, (No Diagnostic Substances)